Acura Pharmaceuticals (STU:HD4B) Total Operating Expense: €2.35 Mil (TTM As of Dec. 2021)


STU:HD4B Acura Pharmaceuticals Inc STU:HD4B
16 GF Score
Price €0.20
View Full Analysis

What is Acura Pharmaceuticals Total Operating Expense?

Acura Pharmaceuticals STU:HD4B 16 Total Operating Expense is €2.35 Mil as of Dec. 2021. GuruFocus rates STU:HD4B with a GF Score™ of 16/100.

Acura Pharmaceuticals's Total Operating Expense for the three months ended in Dec. 2021 was €0.24 Mil. Acura Pharmaceuticals's Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2021 was €2.35 Mil.

Acura Pharmaceuticals Total Operating Expense Related Terms

Acura Pharmaceuticals Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Acura Pharmaceuticals's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Acura Pharmaceuticals Total Operating Expense Chart

Acura Pharmaceuticals Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.81 3.80 3.04 3.56 2.46

Acura Pharmaceuticals Quarterly Data
Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.70 0.66 0.76 0.68 0.24
STU:HD4B
16GF Score
Acura Pharmaceuticals Inc STU:HD4B
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Acura Pharmaceuticals Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was €2.35 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of €2.35 Mil mean?
Acura Pharmaceuticals (STU:HD4B) has a Total Operating Expense of €2.35 Mil as of Dec. 2021. Total operating expense is the primary recurring expense associated with central operations. View historical data on Acura Pharmaceuticals and its competitors.
Is Acura Pharmaceuticals' Total Operating Expense too high?
Acura Pharmaceuticals' current Total Operating Expense is €2.35 Mil. Overall, Acura Pharmaceuticals has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Acura Pharmaceuticals' Total Operating Expense compare to VFRM and THCT?
Acura Pharmaceuticals' Total Operating Expense of €2.35 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Drug Manufacturers company?
A good Total Operating Expense depends on the Drug Manufacturers industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Acura Pharmaceuticals and its competitors. Acura Pharmaceuticals's current Total Operating Expense is €2.35 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acura Pharmaceuticals stock overvalued right now?
Acura Pharmaceuticals (STU:HD4B) has a current Total Operating Expense of €2.35 Mil. The current Total Operating Expense is €2.35 Mil. Acura Pharmaceuticals' overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Acura Pharmaceuticals (STU:HD4B), the current Total Operating Expense is €2.35 Mil as of Dec. 2021. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Acura Pharmaceuticals Business Description

Address 616 N. North Court, Suite 120, Palatine, IL, USA, 60067
Acura Pharmaceuticals Inc is a drug delivery company engaged in the research, development and commercialization of technologies and products intended to address safe use of medications. It has discovered and developed three proprietary platform technologies which can be used to develop multiple products. Its Limitx Technology is being developed to minimize the risk of overdose, its Aversion Technology is intended to address methods of abuse associated with opioid analgesics while its Impede Technology is directed at minimizing the extraction and conversion of pseudoephedrine, or PSE, into methamphetamine. It operates in single segment being the research, development and commercialization of technologies and products intended to address safe use of medications.
16GF Score

Get the complete analysis for STU:HD4B

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.20
Price